2013 – Page 2 – Astex

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

3 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 AACR: Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-11

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

2 November 2013/in 2013, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT